• Gaetano Perchiazzi, Mariangela Pellegrini, Elena Chiodaroli, Ivan Urits, Alan D Kaye, Omar Viswanath, Giustino Varrassi, and Filomena Puntillo.
• Hedenstierna Laboratory, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Central Intensive Care Unit, Department of Anesthesia, Operation and Intensive Care, Uppsala University Hospital, Uppsala, Sweden. Electronic address: gaetano.perchiazzi@surgsci.uu.se.
• Best Pract Res Clin Anaesthesiol. 2020 Sep 1; 34 (3): 561567561-567.

AbstractCoronavirus disease 2019 (COVID-19) is a new disease with different phases that can be catastrophic for subpopulations of patients with cardiovascular and pulmonary disease states at baseline. Appreciation for these different phases and treatment modalities, including manipulation of ventilatory settings and therapeutics, has made it a less lethal disease than when it emerged earlier this year. Different aspects of the disease are still largely unknown. However, laboratory investigation and clinical course of the COVID-19 show that this new disease is not a typical acute respiratory distress syndrome process, especially during the first phase. For this reason, the best strategy to be applied is to treat differently the single phases and to support the single functions of the failing organs as they appear.Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

22 keywords...

hide…